Safety and Efficacy Study of TX103 CAR-T Cell Therapy for Recurrent or Progressive Grade 4 Glioma.

NCT06482905 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

52

Enrollment

INDUSTRY

Sponsor class

Conditions

High-grade Glioma
WHO Grade Ⅳ Glioma

Interventions

BIOLOGICAL: Anti-B7-H3 Chimeric Antigen Receptor T-Cell (CAR-T Cell) Injection/TX103

Sponsor

Tcelltech Inc.

Collaborators

[object Object]
[object Object]